This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated REST Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-REST WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~121.9 kDa | |
| Gel | 8–10% (standard starting point) | |
| Positive control | Bronchus (IHC candidate; verify WB) +4 more | |
| Negative control | Suggested KO / knockdown lysate |
| PTM | Phosphorylated + Ubl conjugation | |
| Caveat | Alternative isoforms | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 4 isoform(s) |
The M03852 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | HeLa cell lysate (catalog M03852) |
| Gel % | 8–10% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Wet/tank transfer; optimize duration (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | M03852; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
UniProt predicts a mass of 121.9 kDa for full-length REST. This is a sequence-based value, not a measured Western blot band position. The selected antibody caption identifies a HeLa lysate but reports no observed molecular mass.
| Signal near the predicted full-length mass | Could be consistent with full-length REST; confirm identity with antibody specificity and appropriate controls. |
| Lower-mass signal | Could reflect an alternative isoform or another source of signal; size alone cannot identify it. |
| Several bands | Evaluate each separately using antibody epitope information and suitable controls. UniProt lists four REST isoforms. |
| Higher-mass signal | Assess its identity experimentally. UniProt lists REST modifications, but does not establish the cause of a higher band. |
| Predicted REST mass | UniProt gives 121.9 kDa for the full-length sequence; empirical gel migration may differ. |
| Isoform 1 | The full-length reference for comparison with the 121.9 kDa predicted mass. |
| Isoform 2 | An alternative sequence lacking residues 314–1097; whether this antibody detects it depends on the epitope. |
| Isoform 3 | An alternative sequence lacking residues 330–1097; whether this antibody detects it depends on the epitope. |
| Isoform 4 | An alternative sequence lacking residues 304–326; whether this antibody detects it depends on the epitope. |
| Situation | Likely cause | Next action |
|---|---|---|
| Band lower than expected | REST has shorter alternative isoforms, but band identity cannot be assigned by position alone. | Check the antibody epitope against each isoform and compare with suitable isoform controls. |
| Multiple bands | Alternative splicing and modifications are possible contributors; other signals also require evaluation. | Assess each band with specificity and isoform controls. |
| Band higher than expected | UniProt annotates phosphorylation and ubiquitin-like conjugation, but neither establishes the cause of a particular shift. | Verify band identity and assess modification only with appropriate controls. |
| Weak or no signal | REST is reported in both nucleus and cytoplasm; abundance and recovery can vary between fractions. | Check sample preparation and compare fractions using fraction controls. |
| Fragments below expected size | A lower band could represent a shorter isoform or another species; its identity is unestablished. | Check whether the antibody epitope is present and compare with isoform-specific controls. |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cervix | squamous epithelial cells | High | Protein (IHC) | HPA → |
| Endometrium | glandular cells | High | Protein (IHC) | HPA → |
| Esophagus | squamous epithelial cells | High | Protein (IHC) | HPA → |
| Fallopian tube | glandular cells | High | Protein (IHC) | HPA → |
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Caudate | glial cells | Low | Protein (IHC) | HPA → |
| Cerebellum | cells in granular layer | Low | Protein (IHC) | HPA → |
| Cerebral cortex | glial cells | Low | Protein (IHC) | HPA → |
| Hippocampus | glial cells | Low | Protein (IHC) | HPA → |
| Liver | cholangiocytes | Low | Protein (IHC) | HPA → |
Deeper troubleshooting and optimisation questions for REST, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Two the supplier anti-REST antibodies are listed with Western blot images. M03852 shows REST/NRSF analysis in HeLa cell lysate; A03852-3 shows REST analysis with reported gel conditions. The supplied evidence does not establish performance across other samples or conditions.
Which to pick: Both listed antibodies have Western blot images. Pick M03852 if a HeLa lysate example is most relevant; consider A03852-3 if its reported 8% SDS-PAGE conditions match your setup. Reactivity beyond the described examples is not specified.